| 翻訳と辞書 |
| Vion Pharmaceuticals ： ウィキペディア英語版 |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. was a New Haven, Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University.
==Clinical Development==
Two anticancer agents, Onrigin (laromustine), formerly cloretazine (VNP40101M), and Triapine, a ribunucloetide reductase inhibitor similar to hydroxyurea, were in human clinical trials. Onrigin (laromustine), a novel alkylating agent, was evaluated in a Phase 2 trial in elderly ''de novo'' poor-risk acute myeloid leukemia (AML). In addition, several trials of Onrigin (laromustine) were conducted in elderly patients with AML and myelodysplastic syndrome (MDS) in combination with cytarabine and in patients with brain tumors in combination with temozolomide. After Onrigin was rejected by the Food and Drug Administration for an AML indication in 2009 due to an unfavorable risk-benefit profile, the company went defunct.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Vion Pharmaceuticals, Inc.」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|